News & Updates
Filter by Specialty:
STRIDE regimen benefit in unresectable HCC consistent across baseline liver function
The overall survival (OS) benefit observed with the STRIDE regimen compared with sorafenib in patients with unresectable hepatocellular carcinoma (HCC) is consistent regardless of baseline liver function, according to exploratory analysis of data from the phase III HIMALAYA trial presented at ESMO GI 2022.
STRIDE regimen benefit in unresectable HCC consistent across baseline liver function
11 Sep 2022
Inflammatory diet ups NAFLD risk, especially in men
A dietary pattern with high inflammatory potential appears to increase the risk of nonalcoholic fatty liver disease (NAFLD), reports a study, adding that this association is greater in men.
Inflammatory diet ups NAFLD risk, especially in men
30 Aug 2022
Probiotics, prebiotics, synbiotics boost metabolism in NAFLD
Patients with nonalcoholic fatty liver disease (NAFLD) who take probiotics, prebiotics, or synbiotics (PPS) may have better energy metabolism, according to a recent study.
Probiotics, prebiotics, synbiotics boost metabolism in NAFLD
19 Aug 2022
Psychotherapy for alcohol use disorder extends benefit to alcohol-related liver disease
Undergoing psychotherapy for alcohol use disorder (AUD) helps prevent the incidence and progression of alcohol-associated liver disease (ALD), according to a study.
Psychotherapy for alcohol use disorder extends benefit to alcohol-related liver disease
18 Aug 2022
HCV reinfection highest among people with ongoing injecting drug use
Reinfection with hepatitis C virus (HCV) is low among people receiving opioid agonist therapy (OAT) but appears to be at its peak during the first 24 weeks following treatment completion and among those with ongoing injecting drug use and needle‒syringe sharing, a study has found.